文献速递传染病防控与疫情报告免疫规划

在非人灵长类中联合使用替考韦马特与ACAM2000™:替考韦马特治疗对ACAM2000免疫原性及抗致死性猴痘病毒攻击保护效果的影响

Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
PubMed 文献 · Vaccine · 2019-10-31

研究在猴子中接种ACAM2000™活减毒天花疫苗并同时给予替考韦马特或安慰剂,评估免疫应答及抗致死性猴痘病毒攻击的保护效果。三项研究中,两项显示体液免疫应答相似,第三项显示疫苗诱导体液免疫降低;攻击后接种/安慰剂组12/12存活,接种/替考韦马特组12/13存活,替考韦马特组临床体征较安慰剂组升高。提示TPOXX可能影响ACAM2000的免疫原性。

要点

  • 两项研究中替考韦马特组与安慰剂组体液免疫应答相似,第三项研究中疫苗诱导体液免疫降低。
  • 致死性猴痘病毒攻击后,接种/安慰剂组12/12存活,接种/替考韦马特组12/13存活。
  • 替考韦马特组临床疾病体征较安慰剂组升高,提示TPOXX可能影响ACAM2000免疫原性。

核心结论

  • 在非人灵长类中,同时给予替考韦马特可能影响ACAM2000™的免疫原性,第三项研究显示疫苗诱导体液免疫降低。
  • 致死性猴痘病毒攻击后,接种/替考韦马特组12/13存活,接种/安慰剂组12/12存活,替考韦马特组临床体征升高。

研究设计与样本

  • 研究在猴子中接种ACAM2000™活减毒天花疫苗,并同时给予替考韦马特或安慰剂。
  • 评估疫苗免疫应答及抗致死性猴痘病毒攻击的保护效果,共三项研究。

主要发现

  • 两项研究中,无论是否接受替考韦马特治疗,初次和回忆性体液免疫应答相似。
  • 第三项研究显示疫苗诱导体液免疫降低。
  • 致死性猴痘病毒攻击后,接种/安慰剂组12/12存活,接种/替考韦马特组12/13存活。
  • 替考韦马特组临床疾病体征较安慰剂组升高。

临床怎么用

  • 作者指出,TPOXX若与ACAM2000同时给药可能影响其免疫原性。
  • 作者认为这些研究可为天花暴发期间疫苗与TPOXX的使用提供参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Naturally occurring smallpox has been eradicated but research stocks of variola virus (VARV), the causative agent of smallpox, still exist in secure laboratories. Clandestine stores of the virus or resurrection of VARV via synthetic biology are possible and have led to concerns that VARV could be used as a biological weapon. The US government has prepared for such an event by stockpiling smallpox vaccines and TPOXX®, SIGA Technologies' smallpox antiviral drug. While vaccination is effective as a pre-exposure prophylaxis, protection is limited when administered following exposure. Safety concerns preclude general use of the vaccine unless there is a smallpox outbreak. TPOXX is approved by the FDA for use after confirmed diagnosis of smallpox disease. Tecovirimat, the active pharmaceutical ingredient in TPOXX, targets a highly conserved orthopoxviral protein, inhibiting long-range dissemination of virus. Although indications for use of the vaccine and TPOXX do not overlap, concomitant use is possible, especially if the TPOXX indication is expanded to include post-exposure prophylaxis. It is therefore important to understand how vaccine and TPOXX may interact. In studies presented here, monkeys were vaccinated with the ACAM2000TM live attenuated smallpox vaccine and concomitantly treated with tecovirimat or placebo. Immune responses to the vaccine and protective efficacy versus a lethal monkeypox virus (MPXV) challenge were evaluated. In two studies, primary and anamnestic humoral immune responses were similar regardless of tecovirimat treatment while the third study showed reduction in vaccine elicited humoral immunity. Following lethal MPXV challenge, all (12 of 12) vaccinated/placebo treated animals survived, and 12 of 13 vaccinated/tecovirimat treated animals survived. Clinical signs of disease were elevated in tecovirimat treated animals compared to placebo treated animals. This suggests that TPOXX may affect the immunogenicity of ACAM2000 if administered concomitantly. These studies may inform on how vaccine and TPOXX are used during a smallpox outbreak.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Russo AT, Berhanu A, Bigger CB, et al. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2019. PMID: 31677948. doi:10.1016/j.vaccine.2019.10.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。